Stocks News

LAST PRICE
148.8500
TODAY'S CHANGE (%)
Trending Down-5.4000 (-3.5008%)

Bid / Lots
145.1000/ 1
Ask / Lots
162.0000/ 1
Open / Previous Close
150.0000 / 154.2500
Day Range
Low 146.9400
High 155.0550
52 Week Range
Low 126.9681
High 229.5662
Volume
287,022
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

May 28, 2024
- BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments, from 9:29AM ET on Tuesday May 28, 2024 by MT Newswires
  9:29AM ET on Tuesday May 28, 2024 by MT Newswires
  Companies Mentioned: BCTX, BGNE
  09:29 AM EDT, 05/28/2024 (MT Newswires) -- BriaCell Therapeutics (BCTX, BCT.TO) said Tuesday it has signed a clinical supply agreement with BeiGene (BGNE) to evaluate the safety and efficacy of its Bria-OTS immunotherapy, in combination with BeiGene...
- BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS(TM) First in Human Study, from 8:00AM ET on Tuesday May 28, 2024 by Dow Jones
  8:00AM ET on Tuesday May 28, 2024 by Dow Jones
  Companies Mentioned: BCT, BGNE
  
  BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS(TM) First in Human Study
  -- Study to evaluate the effects of Bria-OTS(TM) in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer.
May 24, 2024
- BeiGene Says Studies Highlight Effectiveness, Safety of Lymphoma Drug Brukinsa, from 8:36AM ET on Friday May 24, 2024 by MT Newswires
  8:36AM ET on Friday May 24, 2024 by MT Newswires
  Companies Mentioned: BGNE
  08:36 AM EDT, 05/24/2024 (MT Newswires) -- BeiGene (BGNE) said Friday that several new analyses for its drug Brukinsa (zanubrutinib) show its efficacy and safety compared with other Bruton's tyrosine kinase inhibitors for treatment of chronic lympho...
- BRUKINSA(R) Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL, from 6:00AM ET on Friday May 24, 2024 by Dow Jones
  6:00AM ET on Friday May 24, 2024 by Dow Jones
  Companies Mentioned: BGNE
  
  New network meta-analysis demonstrates favorable progression-free survival for patients treated with BRUKINSA vs other BTKi's
  
  Analysis of Kaiser Permanente database shows BRUKINSA effective and generally well tolerated, including in patients switching to BRUKINSA from ibrutinib
May 14, 2024
- BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024, from 4:01PM ET on Tuesday May 14, 2024 by Dow Jones
  4:01PM ET on Tuesday May 14, 2024 by Dow Jones
  Companies Mentioned: BGNE
  
  The most common adverse reactions (>=30%), including laboratory abnormalities, in patients who received BRUKINSA (N=1729) are decreased neutrophil count (51%), decreased platelet count (41%), upper respiratory tract infection (38%), hemorrhage (32%), and musculoskeletal pain (31%).

May 31, 2024
- Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing, from 3:49AM ET on Friday May 31, 2024 by MT Newswires
  3:49AM ET on Friday May 31, 2024 by MT Newswires
  Companies Mentioned: NBIX
- BioMarin Pharmaceutical Insider Sold Shares Worth $3,043,802, According to a Recent SEC Filing, from 3:38AM ET on Friday May 31, 2024 by MT Newswires
  3:38AM ET on Friday May 31, 2024 by MT Newswires
  Companies Mentioned: BMRN
May 28, 2024
- Neurocrine Biosciences Says CEO Kevin Gorman Retiring, from 5:09PM ET on Tuesday May 28, 2024 by MT Newswires
  5:09PM ET on Tuesday May 28, 2024 by MT Newswires
  Companies Mentioned: NBIX
- UBS Raises Price Target on Neurocrine Biosciences to $193 From $174, Maintains Buy Rating, from 9:20AM ET on Tuesday May 28, 2024 by MT Newswires
  9:20AM ET on Tuesday May 28, 2024 by MT Newswires
  Companies Mentioned: NBIX
May 21, 2024
- Neurocrine Biosciences Insider Sold Shares Worth $297,860, According to a Recent SEC Filing, from 5:35PM ET on Tuesday May 21, 2024 by MT Newswires
  5:35PM ET on Tuesday May 21, 2024 by MT Newswires
  Companies Mentioned: NBIX
May 17, 2024
- --Baird Downgrades BioMarin Pharmaceutical to Neutral From Outperform, Cuts Price Target to $72 From $104, from 7:29AM ET on Friday May 17, 2024 by MT Newswires
  7:29AM ET on Friday May 17, 2024 by MT Newswires
  Companies Mentioned: BMRN
May 16, 2024
- Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing, from 4:47PM ET on Thursday May 16, 2024 by MT Newswires
  4:47PM ET on Thursday May 16, 2024 by MT Newswires
  Companies Mentioned: NBIX
- United Therapeutics Insider Sold Shares Worth $545,800, According to a Recent SEC Filing, from 4:41PM ET on Thursday May 16, 2024 by MT Newswires
  4:41PM ET on Thursday May 16, 2024 by MT Newswires
  Companies Mentioned: UTHR
May 14, 2024
- United Therapeutics Insider Sold Shares Worth $1,911,532, According to a Recent SEC Filing, from 4:39PM ET on Tuesday May 14, 2024 by MT Newswires
  4:39PM ET on Tuesday May 14, 2024 by MT Newswires
  Companies Mentioned: UTHR
- Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024, from 8:30AM ET on Tuesday May 14, 2024 by PR Newswire
  8:30AM ET on Tuesday May 14, 2024 by PR Newswire
  Companies Mentioned: NBIX

Beigene Ltd
NASDAQ:BGNEUnited States

Search Criteria

May 28, 2024

BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments, from 9:29AM ET on Tuesday May 28, 2024 by MT Newswires

BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS(TM) First in Human Study, from 8:00AM ET on Tuesday May 28, 2024 by Dow Jones

May 24, 2024

BeiGene Says Studies Highlight Effectiveness, Safety of Lymphoma Drug Brukinsa, from 8:36AM ET on Friday May 24, 2024 by MT Newswires

BRUKINSA(R) Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL, from 6:00AM ET on Friday May 24, 2024 by Dow Jones

May 14, 2024

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024, from 4:01PM ET on Tuesday May 14, 2024 by Dow Jones

Peers Headlines

May 31, 2024

Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing, from 3:49AM ET on Friday May 31, 2024 by MT Newswires

BioMarin Pharmaceutical Insider Sold Shares Worth $3,043,802, According to a Recent SEC Filing, from 3:38AM ET on Friday May 31, 2024 by MT Newswires

May 28, 2024

Neurocrine Biosciences Says CEO Kevin Gorman Retiring, from 5:09PM ET on Tuesday May 28, 2024 by MT Newswires

UBS Raises Price Target on Neurocrine Biosciences to $193 From $174, Maintains Buy Rating, from 9:20AM ET on Tuesday May 28, 2024 by MT Newswires

May 21, 2024

Neurocrine Biosciences Insider Sold Shares Worth $297,860, According to a Recent SEC Filing, from 5:35PM ET on Tuesday May 21, 2024 by MT Newswires

May 17, 2024

--Baird Downgrades BioMarin Pharmaceutical to Neutral From Outperform, Cuts Price Target to $72 From $104, from 7:29AM ET on Friday May 17, 2024 by MT Newswires

May 16, 2024

Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing, from 4:47PM ET on Thursday May 16, 2024 by MT Newswires

United Therapeutics Insider Sold Shares Worth $545,800, According to a Recent SEC Filing, from 4:41PM ET on Thursday May 16, 2024 by MT Newswires

May 14, 2024

United Therapeutics Insider Sold Shares Worth $1,911,532, According to a Recent SEC Filing, from 4:39PM ET on Tuesday May 14, 2024 by MT Newswires

Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024, from 8:30AM ET on Tuesday May 14, 2024 by PR Newswire